These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 20807194

  • 1. Omalizumab for asthma: indications, off-label uses and future directions.
    Ben-Shoshan M.
    Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):183-92. PubMed ID: 20807194
    [Abstract] [Full Text] [Related]

  • 2. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G, Piccolo A, Salzillo A, Noschese P, D'Amato M, Liccardi G.
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [Abstract] [Full Text] [Related]

  • 3. Omalizumab: not only for asthma.
    Ben-Shoshan M.
    Recent Pat Inflamm Allergy Drug Discov; 2008 Nov; 2(3):191-201. PubMed ID: 19076009
    [Abstract] [Full Text] [Related]

  • 4. Anti-IgE antibodies for the treatment of asthma.
    Buhl R.
    Curr Opin Pulm Med; 2005 Jan; 11(1):27-34. PubMed ID: 15591885
    [Abstract] [Full Text] [Related]

  • 5. Anti-IgE and chemotherapy: a critical appraisal of treatment options for severe asthma.
    Walters EH, Walters JA, Wood-Baker R.
    Expert Opin Pharmacother; 2007 Apr; 8(5):585-92. PubMed ID: 17376014
    [Abstract] [Full Text] [Related]

  • 6. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF.
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [Abstract] [Full Text] [Related]

  • 7. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
    Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H.
    Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
    [Abstract] [Full Text] [Related]

  • 8. Omalizumab.
    Easthope S, Jarvis B.
    Drugs; 2001 Apr; 61(2):253-60; discussion 261. PubMed ID: 11270941
    [Abstract] [Full Text] [Related]

  • 9. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
    Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G.
    Eur Respir J; 2001 Aug; 18(2):254-61. PubMed ID: 11529281
    [Abstract] [Full Text] [Related]

  • 10. The relevance of IgE in the pathogenesis of allergy: the effect of an anti-IgE drug in asthma and other diseases.
    Domingo C, Pacheco A, Hinojosa M, Bosque M.
    Recent Pat Inflamm Allergy Drug Discov; 2007 Jun; 1(2):151-64. PubMed ID: 19075978
    [Abstract] [Full Text] [Related]

  • 11. [Anti IgE antibodies for the treatment of difficult asthma].
    Humbert M, Tonnel AB.
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):983-90. PubMed ID: 16222222
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD, Omalizumab 011 International Study Group.
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [Abstract] [Full Text] [Related]

  • 14. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.
    Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taillé C, Devouassoux G, de Blay F, Couderc LJ, Didier A, O'Callaghan DS, Girodet PO, Bourdeix I, Le Gros V, Humbert M.
    Chest; 2013 Aug; 144(2):411-419. PubMed ID: 23579324
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
    Kupryś-Lipińska I, Kuna P.
    Pneumonol Alergol Pol; 2009 Oct; 77(1):43-51. PubMed ID: 19308909
    [Abstract] [Full Text] [Related]

  • 18. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM, QUALITX Study Investigators.
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, Martín M.
    J Immunol Res; 2016 Apr; 2016():8163803. PubMed ID: 28097159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.